Cortactin Polyclonal Antibody

Cortactin, encoded by CTTN gene (formerly EMS1), was originally identified as a substrate of the Src kinase. It is a cytoskeletal protein that interacts with F-actin and Arp2/3 complex and plays an important role in regulation of actin assembly and cytoskeleton dynamics. Overexpression of cortactin increases cell migration, and is thought to contribute to the invasive phennotype of breast cancer and several other tumors. Three isoforms of cortactin exist due to the alternative splicing.

The Cortactin Polyclonal Antibody is a highly specific and sensitive tool designed for the detection and analysis of cortactin protein expression in various biological samples. This antibody is produced using advanced recombinant DNA technology, ensuring high purity and batch-to-batch consistency.

With its exceptional affinity and selectivity, the Cortactin Polyclonal Antibody enables accurate and reliable identification of cortactin in Western blotting, immunohistochemistry, and immunofluorescence applications. It exhibits minimal cross-reactivity with other proteins, ensuring precise and specific results.

The Cortactin Polyclonal Antibody is validated for use in multiple species, including human, mouse, and rat, making it suitable for a wide range of research studies. Its robust performance and versatility make it an indispensable tool for investigating the role of cortactin in cellular processes such as cell migration, adhesion, and invasion.

This antibody is supplied in a convenient liquid format, ready for immediate use. It is provided in a vial with optimal storage conditions, ensuring long-term stability and preserving its functionality. Each batch of the Cortactin Polyclonal Antibody undergoes rigorous quality control testing to guarantee consistent performance and reproducible results.

Choose the Cortactin Polyclonal Antibody for its exceptional sensitivity, specificity, and reliability, and unlock new insights into the intricate mechanisms involving cortactin in various biological processes.